These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931 [TBL] [Abstract][Full Text] [Related]
25. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review. Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ; Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782 [TBL] [Abstract][Full Text] [Related]
26. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. Zhang T; Zhu J; George DJ; Armstrong AJ Expert Opin Pharmacother; 2015 Mar; 16(4):473-85. PubMed ID: 25534660 [TBL] [Abstract][Full Text] [Related]
27. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M Cancer Treat Rev; 2016 Mar; 44():61-73. PubMed ID: 26907461 [TBL] [Abstract][Full Text] [Related]
28. New treatment options for patients with metastatic castration-resistant prostate cancer. Higano CS Cancer Treat Rev; 2012 Aug; 38(5):340-5. PubMed ID: 21944872 [TBL] [Abstract][Full Text] [Related]
30. Potential use of custirsen to treat prostate cancer. Higano CS Onco Targets Ther; 2013; 6():785-97. PubMed ID: 23836992 [TBL] [Abstract][Full Text] [Related]
31. Current treatment strategies for castration-resistant prostate cancer. Kim SJ; Kim SI Korean J Urol; 2011 Mar; 52(3):157-65. PubMed ID: 21461278 [TBL] [Abstract][Full Text] [Related]
32. Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review. Hatano K; Nonomura N World J Mens Health; 2023 Oct; 41(4):769-784. PubMed ID: 36792090 [TBL] [Abstract][Full Text] [Related]
33. Recent advances in second-line treatment of castration-resistant prostate cancer. Ong M; Winquist E Curr Opin Support Palliat Care; 2011 Sep; 5(3):199-205. PubMed ID: 21734586 [TBL] [Abstract][Full Text] [Related]
34. Sequencing of agents for castration-resistant prostate cancer. Hurwitz M; Petrylak DP Oncology (Williston Park); 2013 Nov; 27(11):1144-9, 1154-8. PubMed ID: 24575543 [TBL] [Abstract][Full Text] [Related]
35. [Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come]. Ouzaid I; Ravery V; Pouessel D; Culine S Prog Urol; 2013 Jan; 23(1):1-7. PubMed ID: 23287477 [TBL] [Abstract][Full Text] [Related]